POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia
Abstract
Authors
Y Gil Rojas P Lasalvia AA Garcia Peña